{"id":519667,"date":"2021-07-29T07:04:24","date_gmt":"2021-07-29T11:04:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/"},"modified":"2021-07-29T07:04:24","modified_gmt":"2021-07-29T11:04:24","slug":"kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/","title":{"rendered":"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., July  29, 2021  (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality.<\/p>\n<p>\u201cWe are excited to welcome Karen and Jolly in these important roles as we continue to build the capabilities to establish Kymera as a leading, fully integrated degrader medicines company,\u201d said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. \u201cKaren\u2019s experience in driving organizational and talent strategies in dynamic R&amp;D organizations will be instrumental in supporting our continued growth, while Jolly\u2019s considerable experience in quality assurance for clinical and commercial-stage products will be invaluable as we continue to advance and broaden Kymera\u2019s pipeline of novel protein degraders.\u201d<\/p>\n<p>\n        <strong>Karen Weisbach, Vice President, People and Culture<\/strong><br \/>\n        <br \/>Ms. Weisbach joins Kymera with over 15 years of experience in human resources and operations, designing values-based initiatives to enhance company culture, improve employee experience and manage change in dynamic, innovative organizations in the biopharmaceutical industry. Prior to Kymera, she served in human resource leadership roles at bluebird bio, Inc., including building and leading the global People Partner function responsible for driving talent and organizational strategies with an emphasis on employee engagement, development, and performance.<\/p>\n<p>\n        <strong>Jolly Bhatia, Vice President, Quality<\/strong><br \/>\n        <br \/>Mr. Bhatia joins Kymera with approximately 25 years in quality oversight of manufacturing and clinical trial lifecycle activities including process and product development, clinical and commercial supply chains and new product launch. Prior to Kymera, he served in quality leadership roles at X4 Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Genzyme Corporation. He holds a Bachelor of Pharmacy degree from Birla Institute of Technology and Science and a Master\u2019s degree in Industrial Pharmacy from St. John\u2019s University.<\/p>\n<p>\n        <strong>About Kymera Therapeutics<\/strong><br \/>\n        <br \/>Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera\u2019s Pegasus\u2122 platform enables the discovery of novel small molecule degraders designed to harness the body\u2019s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera\u2019s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R\/TLR or JAK\/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera\u2019s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.<\/p>\n<p>Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a \u201cFierce 15\u201d biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston\u2019s \u201cBest Places to Work.\u201d For more information about our people, science, and pipeline, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NlDZedelrDLQMmx7r1sVl3TCZIv4v5WzWcd_cbw_6f0yZKeUoDeI78htKepXoTA5sHklmK_ya_JUVblxfJ2ElA==\" rel=\"nofollow noopener\" target=\"_blank\">www.kymeratx.com<\/a> or follow us on Twitter or LinkedIn.<\/p>\n<p>\n        <strong><br \/>\n          <u>Cautionary Note Regarding Forward-Looking Statements<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the IRAK4, <\/em><br \/>\n        <em>IRAKIMiD and STAT3 degrader programs<\/em><br \/>\n        <em>; and plans and timelines for the clinical development of Kymera Therapeutics&#8217; product candidates, including the therapeutic potential and clinical benefits thereof. The words &#8220;may,&#8221; \u201cmight,\u201d &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; \u201cexpect,\u201d &#8220;estimate,&#8221; \u201cseek,\u201d &#8220;predict,&#8221; \u201cfuture,\u201d &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of\u00a0Kymera Therapeutics&#8217;\u00a0drug candidates;\u00a0the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials;\u00a0Kymera Therapeutics&#8217; ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company\u2019s planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property.\u00a0These and other risks and uncertainties are described in greater detail in the section entitled &#8220;Risk Factors&#8221; in the Quarterly Report on Form 10-Q for the period ended March 31, 2021, expected to be filed on or about August 5, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics&#8217; subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics&#8217; views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.<\/em>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Paul Cox<br \/>VP, Investor Relations and Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1cUImStsuhCAgSEwP8M5vhky_ScEUxyBRA-yJ51SMo-2ICsuq3bUb7f7VnsMkAUSwORhSsIOXm4m4QBY3mDRiA==\" rel=\"nofollow noopener\" target=\"_blank\">pcox@kymeratx.com<\/a><br \/>917-754-0207<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Lissette L. Steele<br \/>Verge Scientific Communications for Kymera Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gv2riPItMpSOlfGmCaNHvq8Q84Whvzf9qG9Y3_BwI50G_RXRFqIBKoWNgG1sZeHArXJ8W3j-fVNjnPHAqJvqzMj-u_2O7HzGl6pDk_2V0qQH5SKtqosca8tRLXafRmM\" rel=\"nofollow noopener\" target=\"_blank\">lsteele@vergescientific.com<\/a><br \/>202-930-4762<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d659b85d-a757-4263-841f-7724a7268d81\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality. \u201cWe are excited to welcome Karen and Jolly in these important roles as we continue to build the capabilities to establish Kymera as a leading, fully integrated degrader medicines company,\u201d said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. \u201cKaren\u2019s experience in driving organizational and talent strategies in dynamic R&amp;D organizations will be instrumental in supporting our continued growth, while Jolly\u2019s considerable experience in quality assurance for clinical and commercial-stage &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519667","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality. \u201cWe are excited to welcome Karen and Jolly in these important roles as we continue to build the capabilities to establish Kymera as a leading, fully integrated degrader medicines company,\u201d said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. \u201cKaren\u2019s experience in driving organizational and talent strategies in dynamic R&amp;D organizations will be instrumental in supporting our continued growth, while Jolly\u2019s considerable experience in quality assurance for clinical and commercial-stage &hellip; Continue reading &quot;Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T11:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality\",\"datePublished\":\"2021-07-29T11:04:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/\"},\"wordCount\":960,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/\",\"name\":\"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=\",\"datePublished\":\"2021-07-29T11:04:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/","og_locale":"en_US","og_type":"article","og_title":"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality - Market Newsdesk","og_description":"WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality. \u201cWe are excited to welcome Karen and Jolly in these important roles as we continue to build the capabilities to establish Kymera as a leading, fully integrated degrader medicines company,\u201d said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. \u201cKaren\u2019s experience in driving organizational and talent strategies in dynamic R&amp;D organizations will be instrumental in supporting our continued growth, while Jolly\u2019s considerable experience in quality assurance for clinical and commercial-stage &hellip; Continue reading \"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T11:04:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality","datePublished":"2021-07-29T11:04:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/"},"wordCount":960,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/","name":"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=","datePublished":"2021-07-29T11:04:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODk4MiM0MzIxMDc4IzIyMDA4MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-appoints-karen-weisbach-as-vice-president-people-and-culture-and-jolly-bhatia-as-vice-president-quality\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519667"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519667\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}